Floatz logo

Ctx-009

Rectal Cancer

Compass TherapeuticsPhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

113 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB

View all 50 →

Same molecule, other indications

Ctx-009 is also rated in:

colorectal cancerDormant
CCC
Indicative ·
51 / 100
View asset →
colon carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
P1b: Advanced Solid TumorsDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →